Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Cardiovascular Imaging Reports
Published in: Current Cardiovascular Imaging Reports 2/2017

Open Access 01-02-2017 | Cardiac Nuclear Imaging (A Cuocolo and M Petretta, Section Editors)

Novel Noninvasive Nuclear Medicine Imaging Techniques for Cardiac Inflammation

Authors: Malte Kircher, Constantin Lapa

Published in: Current Cardiovascular Imaging Reports | Issue 2/2017

Login to get access

Abstract

Purpose of Review

Inflammation is a key player in a wide range of cardiovascular and myocardial diseases. Given the numerous implications of inflammatory processes in disease initiation and progression, functional imaging modalities including positron emission tomography (PET) represent valuable diagnostic, prognostic, and monitoring tools in patient management. Since increased glucose metabolism is a hallmark of inflammation, PET using the radiolabeled glucose analog [18F]-2-deoxy-2-fluoro-d-glucose (FDG) is the mainstay diagnostic test for nuclear imaging of (cardiac) inflammation. Recently, new approaches using more specific tracers to overcome the limited specificity of FDG have emerged.

Recent Findings

PET imaging has proven its value in a number of inflammatory conditions of the heart including myocarditis, endocarditis, sarcoidosis, or reactive changes after myocardial infarction. In infection-related endocarditis, FDG-PET and white blood cell scintigraphy have been implemented in current guidelines. FDG-PET is considered as nuclear medical gold standard in myocarditis, pericarditis, or sarcoidosis. Novel strategies, including targeting of somatostatin receptors or C-X-C motif chemokine receptor CXCR4, have shown promising results in first studies.

Summary

Nuclear medicine techniques offer valuable information in the assessment of myocardial inflammation. Given the possibility to directly visualize inflammatory activity, they represent useful tools for diagnosis, risk stratification, and therapy monitoring.
Literature
1.
2.
Chu VH et al. Early predictors of in-hospital death in infective endocarditis. Circulation. 2004;109(14):1745–9.PubMedCrossRef
3.
Hill EE et al. Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study. Eur Heart J. 2007;28(2):196–203.PubMedCrossRef
4.
Pant S et al. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. J Am Coll Cardiol. 2015;65(19):2070–6.PubMedCrossRef
5.
6.
Armani C et al. Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. J Leukoc Biol. 2007;81(3):845–55.PubMedCrossRef
7.
Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354(6):610–21.PubMedCrossRef
8.
9.
• Bentzon JF et al. Mechanisms of plaque formation and rupture. Circ Res. 2014;114(12):1852–66. A review comprehensively discussing the mechanisms of atherosclerotic plaque initiation and progression as well as the concepts of plaque burden, activity and vulnerability.
10.
Dimitrijevic O et al. Serial measurements of C-reactive protein after acute myocardial infarction in predicting one-year outcome. Int Heart J. 2006;47(6):833–42.PubMedCrossRef
11.
Prondzinsky R et al. Interleukin-6, −7, −8 and −10 predict outcome in acute myocardial infarction complicated by cardiogenic shock. Clin Res Cardiol. 2012;101(5):375–84.PubMedCrossRef
12.
Kwong RY et al. Detecting acute coronary syndrome in the emergency department with cardiac magnetic resonance imaging. Circulation. 2003;107(4):531–7.PubMedCrossRef
13.
Jung K et al. Endoscopic time-lapse imaging of immune cells in infarcted mouse hearts. Circ Res. 2013;112(6):891–9.PubMedCrossRef
14.
• Lee WW et al. PET/MRI of inflammation in myocardial infarction. J Am Coll Cardiol. 2012;59(2):153–63. A study investigating the spatial and temporal kinetics of cell recruitment after myocardial infarction.PubMedPubMedCentralCrossRef
15.
Rischpler C et al. Prospective evaluation of 18F-fluorodeoxyglucose uptake in postischemic myocardium by simultaneous positron emission tomography/magnetic resonance imaging as a prognostic marker of functional outcome. Circ Cardiovasc Imaging. 2016;9(4):e004316.PubMed
16.
• Wollenweber T et al. Characterizing the inflammatory tissue response to acute myocardial infarction by clinical multimodality noninvasive imaging. Circ Cardiovasc Imaging. 2014;7(5):811–8. A single-center study showing high metabolic rates of glucose in patients after myocardial infarction. Myocardial glucose utilization was associated with splenic and bone marrow activity as sources of inflammatory cells.PubMedCrossRef
17.
Ishimaru S et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J. 2005;26(15):1538–43.PubMedCrossRef
18.
Rogers IS et al. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging. 2010;3(4):388–97.PubMedCrossRef
19.
Morooka M et al. 11C-methionine PET of acute myocardial infarction. J Nucl Med. 2009;50(8):1283–7.PubMedCrossRef
20.
Lapa C et al. Imaging of myocardial inflammation with somatostatin receptor based PET/CT - a comparison to cardiac MRI. Int J Cardiol. 2015;194:44–9.PubMedCrossRef
21.
Thackeray JT et al. Targeting post-infarct inflammation by PET imaging: comparison of (68)Ga-citrate and (68)Ga-DOTATATE with (18)F-FDG in a mouse model. Eur J Nucl Med Mol Imaging. 2015;42(2):317–27.PubMedCrossRef
22.
Bouhlel MA et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007;6(2):137–43.PubMedCrossRef
23.
Finn AV et al. Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques. J Am Coll Cardiol. 2012;59(2):166–77.PubMedCrossRef
24.
• Tahara N et al. 2-deoxy-2-[18F]fluoro-D-mannose positron emission tomography imaging in atherosclerosis. Nat Med. 2014;20(2):215–9. A pre-clinical study describing high uptake of 2-deoxy-2-[(18)F]fluoro-D-mannose in atherosclerotic lesions.PubMedCrossRef
25.
Askari AT et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet. 2003;362(9385):697–703.PubMedCrossRef
26.
Shintani S et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation. 2001;103(23):2776–9.PubMedCrossRef
27.
De Falco E et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood. 2004;104(12):3472–82.PubMedCrossRef
28.
29.
Mayorga M et al. Early upregulation of myocardial CXCR4 expression is critical for dimethyloxalylglycine-induced cardiac improvement in acute myocardial infarction. Am J Physiol Heart Circ Physiol. 2016;310(1):H20–8.PubMedCrossRef
30.
Dong F et al. Myocardial CXCR4 expression is required for mesenchymal stem cell mediated repair following acute myocardial infarction. Circulation. 2012;126(3):314–24.PubMedCrossRef
31.
Jujo K et al. CXC-chemokine receptor 4 antagonist AMD3100 promotes cardiac functional recovery after ischemia/reperfusion injury via endothelial nitric oxide synthase-dependent mechanism. Circulation. 2013;127(1):63–73.PubMedCrossRef
32.
Gupta SK, Pillarisetti K, Lysko PG. Modulation of CXCR4 expression and SDF-1alpha functional activity during differentiation of human monocytes and macrophages. J Leukoc Biol. 1999;66(1):135–43.PubMed
33.
34.
35.
Philipp-Abbrederis K et al. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med. 2015;7(4):477–87.PubMedPubMedCentralCrossRef
36.
37.
Lapa C et al. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience. Oncotarget. 2016;7(8):9288–95.PubMedPubMedCentral
38.
Vag T et al. First experience with chemokine receptor CXCR4-targeted PET imaging of patients with solid cancers. J Nucl Med. 2016;57(5):741–6.PubMedCrossRef
39.
Lapa C et al. [(68)Ga]pentixafor-PET/CT for imaging of chemokine receptor 4 expression after myocardial infarction. JACC Cardiovasc Imaging. 2015;8(12):1466–8.PubMedCrossRef
40.
Thackeray JT et al. Molecular imaging of the chemokine receptor CXCR4 after acute myocardial infarction. JACC Cardiovasc Imaging. 2015;8(12):1417–26.PubMedCrossRef
41.
Li X et al. Targeting P-selectin by gallium-68-labeled fucoidan positron emission tomography for noninvasive characterization of vulnerable plaques: correlation with in vivo 17.6T MRI. Arterioscler Thromb Vasc Biol. 2014;34(8):1661–7.PubMedCrossRef
42.
Sahul ZH et al. Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circ Cardiovasc Imaging. 2011;4(4):381–91.PubMedPubMedCentralCrossRef
43.
Jenkins WS, et al. Cardiac alphaVbeta3 integrin expression following acute myocardial infarction in humans. Heart. 2016.
44.
• Habib G et al. Value and limitations of the Duke criteria for the diagnosis of infective endocarditis. J Am Coll Cardiol. 1999;33(7):2023–9. A study investigating the value of Duke criteria in patients with pathologically proven infective endocarditis. 24% of patients were misclassified despite the use of Duke criteria.PubMedCrossRef
45.
Thuny F et al. Management of infective endocarditis: challenges and perspectives. Lancet. 2012;379(9819):965–75.PubMedCrossRef
46.
•• Saby L et al. Positron emission tomography/computed tomography for diagnosis of prosthetic valve endocarditis: increased valvular 18F-fluorodeoxyglucose uptake as a novel major criterion. J Am Coll Cardiol. 2013;61(23):2374–82. A prospective study investigating the use of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for diagnosing prosthetic valve endocarditis (PVE). FDG uptake aorund the site of the prosthetic valve had a global accuracy in diagnosing PVE of 76%.PubMedCrossRef
47.
• Granados U et al. Diagnostic accuracy of 18F-FDG PET/CT in infective endocarditis and implantable cardiac electronic device infection: a cross-sectional study. J Nucl Med. 2016;57(11):1726–32. A prospective study investigating the use of FDG-PET/CT for diagnosing infective endocarditis and implantable cardiac electronic device infection. Sensitivity and specificity of PET were 82% and 96%, respectively. PET also identified cases of septic embolism and/or malignancy.PubMedCrossRef
48.
Van Riet J et al. (18)F-FDG PET/CT for early detection of embolism and metastatic infection in patients with infective endocarditis. Eur J Nucl Med Mol Imaging. 2010;37(6):1189–97.PubMedCrossRef
49.
Asmar A et al. Clinical impact of 18F-FDG-PET/CT in the extra cardiac work-up of patients with infective endocarditis. Eur Heart J Cardiovasc Imaging. 2014;15(9):1013–9.PubMedCrossRef
50.
Balmforth D, Chacko J, Uppal R. Does positron emission tomography/computed tomography aid the diagnosis of prosthetic valve infective endocarditis? Interact Cardiovasc Thorac Surg. 2016;23(4):648–52.PubMedCrossRef
51.
Bonfiglioli R et al. (1)(8)F-FDG PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with suspected cardiac endocarditis. Eur J Nucl Med Mol Imaging. 2013;40(8):1190–6.PubMedCrossRef
52.
Ozcan C et al. The value of FDG-PET/CT in the diagnostic work-up of extra cardiac infectious manifestations in infectious endocarditis. Int J Cardiovasc Imaging. 2013;29(7):1629–37.PubMedCrossRef
53.
•• Pizzi MN et al. Improving the diagnosis of infective endocarditis in prosthetic valves and intracardiac devices with 18F-fluordeoxyglucose positron emission tomography/computed tomography angiography: initial results at an Infective Endocarditis Referral Center. Circulation. 2015;132(12):1113–26. A single-center study demonstrating improved accuracy in the diagnosis of infective endocarditis and prosthetic valves or cardiac devices by use of FDG-PET/CT. Addition of CT angiography yielded additional benefit.PubMedCrossRef
54.
Lancellotti P et al. Positron emission tomography/computed tomography imaging in device infective endocarditis: ready for prime time. Circulation. 2015;132(12):1076–80.PubMedCrossRef
55.
• Habib G et al. 2015 ESC Guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075–128. Recent guidelines stressing the value of FDG-PET/CT in diagnosis of infective endocarditis.PubMedCrossRef
56.
Millar BC et al. 18FDG-positron emission tomography (PET) has a role to play in the diagnosis and therapy of infective endocarditis and cardiac device infection. Int J Cardiol. 2013;167(5):1724–36.PubMedCrossRef
57.
Sarrazin JF et al. Usefulness of fluorine-18 positron emission tomography/computed tomography for identification of cardiovascular implantable electronic device infections. J Am Coll Cardiol. 2012;59(18):1616–25.PubMedCrossRef
58.
Cerqueira MD, Jacobson AF. Indium-111 leukocyte scintigraphic detection of myocardial abscess formation in patients with endocarditis. J Nucl Med. 1989;30(5):703–6.PubMed
59.
Erba PA et al. Radiolabeled WBC scintigraphy in the diagnostic workup of patients with suspected device-related infections. JACC Cardiovasc Imaging. 2013;6(10):1075–86.PubMedCrossRef
60.
Rouzet F et al. Respective performance of 18F-FDG PET and radiolabeled leukocyte scintigraphy for the diagnosis of prosthetic valve endocarditis. J Nucl Med. 2014;55(12):1980–5.PubMedCrossRef
61.
Adjtoutah D et al. Advantages of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in detecting post cardiac surgery infections. J Saudi Heart Assoc. 2014;26(1):57–61.PubMedCrossRef
62.
Thuny F et al. Reply: positron emission tomography/computed tomography for diagnosis of prosthetic valve endocarditis. J Am Coll Cardiol. 2014;63(2):187–9.PubMedCrossRef
63.
• Caobelli F, et al. Simultaneous dual-isotope solid-state detector SPECT for improved tracking of white blood cells in suspected endocarditis. Eur Heart J. 2016. A single center study demonstrating the feasiblity of simultaneous perfusion and inflammation imaging in suspected endocarditis.
64.
Pinkston KL et al. Antibody guided molecular imaging of infective endocarditis. Methods Mol Biol. 2017;1535:229–41.PubMedCrossRef
65.
Tarakji KG et al. Cardiac implantable electronic device infections: presentation, management, and patient outcomes. Heart Rhythm. 2010;7(8):1043–7.PubMedCrossRef
66.
Cautela J et al. Diagnostic yield of FDG positron-emission tomography/computed tomography in patients with CEID infection: a pilot study. Europace. 2013;15(2):252–7.PubMedCrossRef
67.
Leccisotti L et al. Cardiovascular implantable electronic device infection: delayed vs standard FDG PET-CT imaging. J Nucl Cardiol. 2014;21(3):622–32.PubMedCrossRef
68.
Bensimhon L et al. Whole body [(18) F]fluorodeoxyglucose positron emission tomography imaging for the diagnosis of pacemaker or implantable cardioverter defibrillator infection: a preliminary prospective study. Clin Microbiol Infect. 2011;17(6):836–44.PubMedCrossRef
69.
Yeh CL et al. Infective endocarditis detected by (1)(8)F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in a patient with occult infection. Kaohsiung J Med Sci. 2011;27(11):528–31.PubMedCrossRef
70.
Kim J et al. FDG PET/CT imaging for LVAD associated infections. JACC Cardiovasc Imaging. 2014;7(8):839–42.PubMedCrossRef
71.
Litzler PY et al. Leukocyte SPECT/CT for detecting infection of left-ventricular-assist devices: preliminary results. J Nucl Med. 2010;51(7):1044–8.PubMedCrossRef
72.
Dell'Aquila AM et al. Contributory role of fluorine 18-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis and clinical management of infections in patients supported with a continuous-flow left ventricular assist device. Ann Thorac Surg. 2016;101(1):87–94. discussion 94.PubMedCrossRef
73.
Tlili G et al. High performances of (18)F-fluorodeoxyglucose PET-CT in cardiac implantable device infections: a study of 40 patients. J Nucl Cardiol. 2015;22(4):787–98.PubMedCrossRef
74.
Amraoui S et al. Contribution of PET imaging to the diagnosis of septic embolism in patients with pacing lead endocarditis. JACC Cardiovasc Imaging. 2016;9(3):283–90.PubMedCrossRef
75.
Caldarella C et al. Which is the optimal acquisition time for FDG PET/CT imaging in patients with infective endocarditis? J Nucl Cardiol. 2013;20(2):307–9.PubMedCrossRef
76.
Glaudemans AW, Israel O, Slart RH. Pitfalls and limitations of radionuclide and hybrid imaging in infection and inflammation. Semin Nucl Med. 2015;45(6):500–12.PubMedCrossRef
77.
De Winter F et al. Promising role of 18-F-fluoro-D-deoxyglucose positron emission tomography in clinical infectious diseases. Eur J Clin Microbiol Infect Dis. 2002;21(4):247–57.PubMedCrossRef
78.
Cooper LT et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J. 2007;28(24):3076–93.PubMedCrossRef
79.
Hauck AJ, Kearney DL, Edwards WD. Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin Proc. 1989;64(10):1235–45.PubMedCrossRef
80.
Friedrich MG, Marcotte F. Cardiac magnetic resonance assessment of myocarditis. Circ Cardiovasc Imaging. 2013;6(5):833–9.PubMedCrossRef
81.
82.
Lurz P et al. Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. JACC Cardiovasc Imaging. 2012;5(5):513–24.PubMedCrossRef
83.
Ozawa K et al. Determination of optimum periods between onset of suspected acute myocarditis and (1)(8)F-fluorodeoxyglucose positron emission tomography in the diagnosis of inflammatory left ventricular myocardium. Int J Cardiol. 2013;169(3):196–200.PubMedCrossRef
84.
Takano H et al. Active myocarditis in a patient with chronic active Epstein-Barr virus infection. Int J Cardiol. 2008;130(1):e11–3.PubMedCrossRef
85.
von Olshausen G et al. Detection of acute inflammatory myocarditis in Epstein Barr virus infection using hybrid 18F-fluoro-deoxyglucose-positron emission tomography/magnetic resonance imaging. Circulation. 2014;130(11):925–6.CrossRef
86.
Nensa F, et al. Feasibility of FDG-PET in myocarditis: comparison to CMR using integrated PET/MRI. J Nucl Cardiol. 2016.
87.
Guralnik L et al. Metabolic PET/CT-guided lung lesion biopsies: impact on diagnostic accuracy and rate of sampling error. J Nucl Med. 2015;56(4):518–22.PubMedCrossRef
88.
Simonen P et al. F-18-fluorodeoxyglucose positron emission tomography-guided sampling of mediastinal lymph nodes in the diagnosis of cardiac sarcoidosis. Am J Cardiol. 2015;116(10):1581–5.PubMedCrossRef
89.
Piriou N et al. Utility of cardiac FDG-PET imaging coupled to magnetic resonance for the management of an acute myocarditis with non-informative endomyocardial biopsy. Eur Heart J Cardiovasc Imaging. 2015;16(5):574.PubMedCrossRef
90.
Nensa F et al. Hybrid PET/MR imaging of the heart: feasibility and initial results. Radiology. 2013;268(2):366–73.PubMedCrossRef
91.
Nensa F et al. Multiparametric assessment of myocarditis using simultaneous positron emission tomography/magnetic resonance imaging. Eur Heart J. 2014;35(32):2173.PubMedCrossRef
92.
Maya Y et al. 11C-methionine PET of myocardial inflammation in a rat model of experimental autoimmune myocarditis. J Nucl Med. 2016;57(12):1985–90.PubMedCrossRef
93.
Alter P et al. MR, CT, and PET imaging in pericardial disease. Heart Fail Rev. 2013;18(3):289–306.PubMedCrossRef
94.
Losik SB, Studentsova Y, Margouleff D. Chemotherapy-induced pericarditis on F-18 FDG positron emission tomography scan. Clin Nucl Med. 2003;28(11):913–5.PubMedCrossRef
95.
Salomaki SP et al. Visualization of pericarditis by fluorodeoxyglucose PET. Eur Heart J Cardiovasc Imaging. 2014;15(3):291.PubMedCrossRef
96.
Shao D et al. Differentiation of malignant from benign heart and pericardial lesions using positron emission tomography and computed tomography. J Nucl Cardiol. 2011;18(4):668–77.PubMedCrossRef
97.
Dong A et al. (18)F-FDG PET/CT in differentiating acute tuberculous from idiopathic pericarditis: preliminary study. Clin Nucl Med. 2013;38(4):e160–5.PubMedCrossRef
98.
99.
Patel D et al. Sarcoid pericarditis and large vessel vasculitis detected on FDG PET/CT. Clin Nucl Med. 2016;41(8):661–3.PubMedCrossRef
100.
Baughman RP et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1885–9.PubMedCrossRef
101.
Mehta D et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008;133(6):1426–35.PubMedCrossRef
102.
103.
Gideon NM, Mannino DM. Sarcoidosis mortality in the United States 1979–1991: an analysis of multiple-cause mortality data. Am J Med. 1996;100(4):423–7.PubMedCrossRef
104.
Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol. 2009;20(5):578–83.PubMedCrossRef
105.
•• Blankstein R et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63(4):329–36. Single-center study demonstrating the prognostic value of FDG-PET/CT in patients with cardiac sarcoidosis. Presence of focal FDG uptake on cardiac PET identified patients at higher risk of death or ventricular tachyarrhythmia.PubMedCrossRef
106.
Youssef G et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53(2):241–8.PubMedCrossRef
107.
Tang R et al. Impact of patient preparation on the diagnostic performance of 18F-FDG PET in cardiac sarcoidosis: a systematic review and meta-analysis. Clin Nucl Med. 2016;41(7):e327–39.PubMedCrossRef
108.
McArdle B et al. Cardiac PET: metabolic and functional imaging of the myocardium. Semin Nucl Med. 2013;43(6):434–48.PubMedCrossRef
109.
110.
111.
Schneider S et al. Utility of multimodal cardiac imaging with PET/MRI in cardiac sarcoidosis: implications for diagnosis, monitoring and treatment. Eur Heart J. 2014;35(5):312.PubMedCrossRef
112.
Ambrosini V et al. (18)F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis: results of a preliminary prospective study. Clin Nucl Med. 2013;38(4):e171–7.PubMedCrossRef
113.
Harisankar CN et al. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol. 2011;18(5):926–36.PubMedCrossRef
114.
Ito K et al. Efficacy of heparin loading during an 18F-FDG PET/CT examination to search for cardiac sarcoidosis activity. Clin Nucl Med. 2013;38(2):128–30.PubMedCrossRef
115.
Mc Ardle BA et al. The role of F(18)-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis. J Nucl Cardiol. 2013;20(2):297–306.PubMedCrossRef
116.
Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol. 2008;190(2):W151–6.PubMedCrossRef
117.
Lapa C, et al. Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI. Oncotarget. 2016.
118.
119.
Reiter T et al. Detection of cardiac sarcoidosis by macrophage-directed somatostatin receptor 2-based positron emission tomography/computed tomography. Eur Heart J. 2015;36(35):2404.PubMedCrossRef
120.
Manabe O, et al. 18F-fluoromisonidazole (FMISO) PET may have the potential to detect cardiac sarcoidosis. J Nucl Cardiol. 2016.
121.
Norikane T et al. 18F-FLT PET imaging in a patient with sarcoidosis with cardiac involvement. Clin Nucl Med. 2015;40(5):433–4.PubMedCrossRef
122.
Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol. 1982;49(1):9–13.PubMedCrossRef
123.
•• Gillmore JD et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–12. Multi-center trial demonstrating the feasibility of nonbiopsy diagnosis of ATTR amyloidosis by means of scintigraphy and serum analysis (to rule out monoclonal gammopathy).PubMedCrossRef
124.
Glaudemans AW et al. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretinderived systemic amyloidosis. Amyloid. 2014;21(1):35–44.PubMedCrossRef
125.
Van Der Gucht A et al. [18F]-NaF PET/CT imaging in cardiac amyloidosis. J Nucl Cardiol. 2016;23(4):846–9.CrossRef
126.
Gagliardi C, et al. Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET/CT? J Nucl Cardiol. 2016.
127.
Trivieri MG et al. 18F-sodium fluoride PET/MR for the assessment of cardiac amyloidosis. J Am Coll Cardiol. 2016;68(24):2712–4.PubMedCrossRef
128.
Kung J et al. Intense fluorodeoxyglucose activity in pulmonary amyloid lesions on positron emission tomography. Clin Nucl Med. 2003;28(12):975–6.PubMedCrossRef
129.
Mekinian A et al. 18F-FDG PET/CT in patients with amyloid light-chain amyloidosis: caseseries and literature review. Amyloid. 2012;19(2):94–8.PubMedCrossRef
130.
Lee SP et al. 11C-Pittsburgh B PET imaging in cardiac amyloidosis. JACC Cardiovasc Imaging. 2015;8(1):50–9.PubMedCrossRef
131.
Pilebro B et al. Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR). J Nucl Cardiol. 2016.
132.
Dorbala S et al. Imaging cardiac amyloidosis: a pilot study using (1)(8)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41(9):1652–62.PubMedCrossRef
133.
Osborne DR et al. A routine PET/CT protocol with streamlined calculations for assessing cardiac amyloidosis using (18)F-florbetapir. Front Cardiovasc Med. 2015;2:23.PubMedPubMedCentralCrossRef
134.
Law WP et al. Cardiac amyloid imaging with 18F-florbetaben PET: a pilot study. J Nucl Med. 2016;57(11):1733–9.PubMedCrossRef
Metadata
Title
Novel Noninvasive Nuclear Medicine Imaging Techniques for Cardiac Inflammation
Authors
Malte Kircher
Constantin Lapa
Publication date
01-02-2017
Publisher
Springer US
Published in
Current Cardiovascular Imaging Reports / Issue 2/2017
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI
https://doi.org/10.1007/s12410-017-9400-x